The Latest Cardiac and Vascular News
QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive Phase 3 eplontersen ATTRv-PN data; December 22, 2023 PDUFA date On track to achieve 2023 financial guidance CARLSBAD, Calif., May 3, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the first quarter of 2023. Financial results are summarized below: […]
ALAMEDA, Calif., May 2, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2023. Revenue of $241.4 million in the first quarter of 2023, an increase of 18.4%, or 19.7% in constant currency1, compared to the first quarter of […]
CARLSBAD, Calif., May 02, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on May 1, 2023 that were approved by the Compensation Committee of its Board of […]
— Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives — — Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing — — International Strategy Progressing with CSL Seqirus Partnership for Australia […]
– Transaction values Avertix at an enterprise value of $195 million – Avertix developed the Guardian™ System, the first and only FDA-approved solution designed to detect and warn patients of cardiac events, including silent heart attacks EATONTOWN, N.J. and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) — Avertix Medical, Inc. (“Avertix” or […]
NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key […]
Pivotal U.S. and Canada STAR-T Trial enrollment enters the last third of the study. Strong customer demand from Q4 2022 continued into Q1 2023, with current expectation of overall sales growth in 2023 PRINCETON, N.J., May 02, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening […]
Partnership Reinforces USHV’s Position as a Leading Cardiovascular Practice Management Organization and Will Drive Efforts to Transform How Quality Cardiovascular Care Is Delivered NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), a leading national provider of support services to cardiovascular physician practices, announced today that it has entered into an agreement […]
HeartBeam to Focus on Becoming the Global Leader in Ambulatory Vectorcardiography, the Highest Resolution ECG Monitoring Platform Funding to Enable Company to Execute on Upcoming Clinical, Regulatory and Commercial Milestones, Extends Cash Runway into Late 2024 HeartBeam to Host Conference Call to Discuss Financing, Strategic Initiatives and First Quarter 2023 […]
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its Combined Annual Shareholders Meeting was held on May 2, 2023 at Espace Encan, La Rochelle, under […]
